Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.

摘要: BACKGROUND Treatment with intravenous clomipramine is rapidly effective in some obsessive-compulsive disorder (OCD) patients unresponsive to orally administered serotonin reuptake inhibitors (SRIs). The selective inhibitor citalopram for OCD when orally. We investigated whether would benefit SRIs. METHOD Thirty-nine adult outpatients participated a 3-week open-label trial of citalopram. Eligible had moderate-to-severe DSM-IV > or = 1 year's duration, baseline Yale-Brown Obsessive Compulsive Scale (YBOCS) score 25, and no other active Axis I diagnosis failed at least 2 adequate oral SRI trials, excluding Intravenous was daily 21 days, followed by until treatment day 84. started 20 mg/day increased 40 80 as tolerated. RESULTS well tolerated even higher doses (dropout rate 2.6%). At 21, 23 (59%) the 39 YBOCS decreases 25%, whom 4 35%. Twenty-seven 20% were allowed continue on citalopram, 84, all substantial further improvement. All 27 also showed significant improvement several dimensions quality life. CONCLUSION safe group treatment-resistant patients. early onset response suggests means accelerating symptom relief predicting treatment. Double-blind, double-dummy, placebo-controlled trials versus are indicated.